Holen Sie sich die Stockscreener-App
36.33
5.89%
2.16
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt ALKS?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$34.17
Offen:
$35.25
24-Stunden-Volumen:
2.12M
Relative Volume:
0.96
Marktkapitalisierung:
$6.04B
Einnahmen:
$1.48B
Nettoeinkommen (Verlust:
$241.66M
KGV:
25.36
EPS:
1.4325
Netto-Cashflow:
$480.33M
1W Leistung:
+5.98%
1M Leistung:
+3.85%
6M Leistung:
+16.45%
1J Leistung:
+15.23%
1-Tages-Spanne:
$34.07
$36.55
1-Wochen-Bereich:
$33.12
$36.55
52-Wochen-Spanne:
$25.16
$36.55
Alkermes Plc Stock (ALKS) Company Profile
Firmenname
Alkermes Plc
Sektor
Telefon
00-353-1-772-8000
Adresse
CONNAUGHT HOUSE, DUBLIN 4
Compare ALKS vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALKS
Alkermes Plc
|
36.33 | 5.68B | 1.48B | 241.66M | 480.33M | 1.4325 |
TAK
Takeda Pharmaceutical Co Adr
|
16.54 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.58 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.88 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.195 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
571.32 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Alkermes Plc Stock (ALKS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-02-24 | Eingeleitet | Wolfe Research | Outperform |
| 2025-11-11 | Eingeleitet | Truist | Buy |
| 2025-09-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2025-09-03 | Eingeleitet | Wells Fargo | Overweight |
| 2025-07-15 | Eingeleitet | Goldman | Buy |
| 2025-06-17 | Hochstufung | UBS | Neutral → Buy |
| 2025-05-28 | Eingeleitet | Needham | Buy |
| 2025-03-13 | Eingeleitet | RBC Capital Mkts | Sector Perform |
| 2025-03-04 | Hochstufung | UBS | Sell → Neutral |
| 2025-02-11 | Eingeleitet | Deutsche Bank | Buy |
| 2024-11-05 | Hochstufung | Stifel | Hold → Buy |
| 2024-06-17 | Eingeleitet | TD Cowen | Buy |
| 2024-03-19 | Eingeleitet | Robert W. Baird | Outperform |
| 2024-02-20 | Herabstufung | UBS | Neutral → Sell |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-24 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-10-17 | Eingeleitet | UBS | Neutral |
| 2022-11-03 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2022-10-14 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2022-08-16 | Eingeleitet | Piper Sandler | Neutral |
| 2022-04-22 | Fortgesetzt | Goldman | Buy |
| 2022-04-20 | Eingeleitet | Goldman | Buy |
| 2022-01-27 | Hochstufung | Cantor Fitzgerald | Hold → Overweight |
| 2021-12-01 | Eingeleitet | Citigroup | Neutral |
| 2021-10-07 | Hochstufung | Jefferies | Hold → Buy |
| 2021-09-02 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2020-10-15 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-07-30 | Herabstufung | Goldman | Neutral → Sell |
| 2020-02-14 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2020-02-14 | Bestätigt | H.C. Wainwright | Neutral |
| 2020-02-14 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-01-31 | Hochstufung | Wolfe Research | Underperform → Peer Perform |
| 2019-09-05 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2019-07-15 | Hochstufung | Goldman | Sell → Neutral |
| 2019-05-31 | Eingeleitet | H.C. Wainwright | Neutral |
| 2019-05-01 | Herabstufung | Citigroup | Buy → Neutral |
| 2018-12-19 | Herabstufung | Goldman | Neutral → Sell |
| 2018-12-14 | Eingeleitet | Wolfe Research | Underperform |
| 2018-12-13 | Herabstufung | Credit Suisse | Outperform → Underperform |
| 2018-11-05 | Eingeleitet | Piper Jaffray | Neutral |
| 2018-08-07 | Eingeleitet | Stifel | Hold |
| 2018-06-21 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2018-06-06 | Eingeleitet | B. Riley FBR, Inc. | Buy |
| 2018-05-16 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-05-11 | Eingeleitet | BofA/Merrill | Buy |
Alle ansehen
Alkermes Plc Aktie (ALKS) Neueste Nachrichten
Stifel raises Alkermes stock price target on orexin pipeline progress - Investing.com
Alkermes Q1 2026 slides: Avadel deal drives revenue beat - Investing.com
Alkermes plc Reports First Quarter 2026 Financial Results - BioSpace
ALKS: Q1 2026 delivered robust sales growth, expanded sleep medicine presence, and advanced orexin pipeline - TradingView
Earnings call transcript: Alkermes Q1 2026 results beat expectations, stock rises - Investing.com
Alkermes Plc reports results for the quarter ended March 31Earnings Summary - TradingView
Alkermes (ALKS) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates - Yahoo Finance
Alkermes (ALKS) Reports Q1 Loss, Beats Revenue Estimates - Yahoo! Finance Canada
Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss - ChartMill
Alkermes rises as quarterly loss narrows, tops estimates - Investing.com
(ALKS) Alkermes Expects 2026 Revenue Range $1.73B$1.84B, vs. FactSet Est of $1.80B - marketscreener.com
Earnings Flash (ALKS) Alkermes Posts Q1 Net Loss $0.40 a Share, vs. FactSet Est of $0.58 Loss - marketscreener.com
Alkermes reports Q1 2026: Revenues $392.9M, GAAP loss $66.5M, Adjusted EBITDA $80.3M - TradingView
Alkermes: Q1 Earnings Snapshot - KING5.com
Avadel deal drives Alkermes (NASDAQ: ALKS) Q1 growth and 2026 EBITDA upgrade - Stock Titan
Alkermes Q1 2026 earnings preview - MSN
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? By Investing.com - Investing.com Nigeria
Alkermes earnings on deck: Can Lumryz offset Avadel deal costs? - Investing.com
ALKS SEC FilingsAlkermes Plc 10-K, 10-Q, 8-K Forms - Stock Titan
Avadel Pharmaceuticals 2025 Financial Results, Alkermes Acquisition, and LUMRYZ Commercial Highlights - Minichart
Alkermes (NASDAQ:ALKS) EVP Sells $300,600.00 in Stock - MarketBeat
Alkermes (NASDAQ: ALKS) EVP exercises 5,000 options and sells 9,000 shares - Stock Titan
Alkermes (NASDAQ: ALKS) details Avadel buyout terms and 2025 results - Stock Titan
Alkermes plc (NASDAQ: ALKS) insider sales, option exercise and PSU vesting noted - Stock Titan
Behavioral Patterns of ALKS and Institutional Flows - Stock Traders Daily
Alkermes plc $ALKS Shares Bought by Pictet Asset Management Holding SA - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Has $5.44 Million Stock Position in Alkermes plc $ALKS - MarketBeat
Alkermes (NASDAQ:ALKS) Rating Increased to Hold at Zacks Research - MarketBeat
Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential - ChartMill
Do options traders know something about Alkermes stock we don't? - MSN
Vanguard Portfolio Management (NASDAQ: ALKS) reports 9.65M shares beneficially owned - Stock Titan
Alkermes (ALKS) Expected to Announce Earnings on Tuesday - MarketBeat
Wall Street Analysts Believe Alkermes (ALKS) Could Rally 29.14%: Here's is How to Trade - Zacks Investment Research
Vanguard holds 8.68M shares in Alkermes (NASDAQ: ALKS) via Schedule 13G - Stock Titan
Earnings Preview: Alkermes (ALKS) Q1 Earnings Expected to Decline - Yahoo Finance
Alkermes plc Announces CEO Succession Plan - Quantisnow
Alkermes announces CEO succession plan - MSN
Are options traders betting on a big move in Alkermes stock? - MSN
Wells Fargo Maintains Alkermes (ALKS) Overweight Recommendation - MSN
Alkermes plc (ALKS) Investor Outlook: Analyzing a 32.80% Upside Potential Amidst a Challenging Year - DirectorsTalk Interviews
Avadel Stock Rises After Acquisition Offer By Alkermes - MSN
Did New Alixorexton Data and LYBALVI Outcomes Just Shift Alkermes' (ALKS) Neuroscience Investment Narrative? - Yahoo Finance
ALKS stock surges 15% on Lilly-Centessa buyout igniting sleep pipeline hopes - MSN
Abacus FCF Advisors LLC Makes New Investment in Alkermes plc $ALKS - MarketBeat
Alkermes plc (NASDAQ:ALKS) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Alkermes (NASDAQ:ALKS) Share Price Crosses Above 200-Day Moving AverageHere's What Happened - MarketBeat
Do Options Traders Know Something About Alkermes Stock We Don't? - TradingView
Alkermes to Report First Quarter Financial Results on May 5, 2026 - 富途牛牛
Is It Too Late To Consider Alkermes (ALKS) After Its Recent 19% Share Price Jump? - simplywall.st
Alkermes (ALKS) nears 52-week high on increasing orexin receptor market interest - MSN
Finanzdaten der Alkermes Plc-Aktie (ALKS)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.41%
2.82%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):